{"filings":[{"id":1303877,"accession_number":"0001171843-26-004324","cik":1041934,"company_name":"EDAP TMS SA","ticker":"EDAP","form_type":"8-K","filed_at":"2026-06-26T20:05:17+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"EDAP TMS shareholders approve bylaw amendments, reject two say-on-pay frequency options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees re-elected; Ryan Rhodes, Lance Willsey, Fran Schulz, Josh Levine, and David Horn confirmed.","Non-binding say-on-pay frequency: annual approved; every-two-years and every-three-years rejected by ~29M votes each.","Resolution for employee share capital increase under French Labor Code not approved (~28.9M against).","Amendments to Articles 7, 8, 14, 22 of bylaws approved with >36M votes for each.","Approximately 37.5M ordinary shares (including ADRs) were voted at the June 26, 2026 Annual General Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":161547358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":777926,"accession_number":"0001171843-26-003840","cik":1041934,"company_name":"EDAP TMS SA","ticker":"EDAP","form_type":"8-K","filed_at":"2026-06-01T20:05:28+00:00","items":["7.01","9.01"],"status":"ready","headline":"EDAP TMS holds FocalTherics Investor Day; plans to exit ESWL and distribution segments to focus on HIFU","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Presentation at June 1, 2026 Investor Day highlights strategic shift to High Intensity Focused Ultrasound (HIFU) devices.","Company intends to discontinue Extracorporeal Shock Wave Lithotripsy (ESWL) and distribution operating segments.","FocalTherics (Nasdaq: FOCL) is the new corporate branding; no financial results or guidance disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":161547358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":731396,"accession_number":"0001171843-26-003773","cik":1041934,"company_name":"EDAP TMS SA","ticker":"EDAP","form_type":"8-K","filed_at":"2026-05-29T11:30:18+00:00","items":["8.01"],"status":"ready","headline":"EDAP TMS rebrands as FocalTherics, ticker to FOCL June 1; ESWL/Distribution discontinued ops","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corporate name changes to FocalTherics; ticker symbol switches from EDAP to FOCL effective June 1, 2026.","Legal name remains EDAP TMS S.A.; shareholder vote required for future legal name change.","Company intends to report ESWL and Distribution segments as discontinued operations starting Q2 2026.","Investor Day on June 1, 2026 at 8:00 AM ET to discuss strategy, new identity, and business outlook.","Shareholders need no action; CUSIP unchanged; ADSs continue trading on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":161547358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90796,"accession_number":"0001171843-26-003113","cik":1041934,"company_name":"EDAP TMS SA","ticker":"EDAP","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EDAP Q1 2026: record HIFU revenue $11.6M (+78% YoY); net loss $9.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["HIFU revenue $11.6M, up 78% YoY; total revenue $17.8M vs $14.3M in Q1 2025.","Eleven Focal One systems sold (+83% YoY); U.S. HIFU procedures up 53% YoY.","Gross margin improved to 45.7% from 42.0% on favorable HIFU mix.","Reiterated FY 2026 HIFU revenue guidance $50-54M; non-core $22-26M.","HIFI-2 study in European Urology Oncology supports Focal One for salvage HIFU after radiation failure."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":17812000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":161547358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90795,"accession_number":"0001171843-26-002218","cik":1041934,"company_name":"EDAP TMS SA","ticker":"EDAP","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["2.03","3.02"],"status":"ready","headline":"EDAP TMS draws €12M second tranche from EIB credit facility; issues warrants at €3.23 strike","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drawdown of €12.0 million under Tranche B of EIB credit facility, expected disbursement late April 2026.","Tranche B matures five years from disbursement; interest payable at maturity.","Issued 1,116,244 Tranche B warrants to EIB with exercise price of €3.23 per ordinary share.","Total facility capacity €36.0 million across three tranches; all terms per Oct 17, 2025 agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":161547358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100600,"accession_number":"0001171843-26-001889","cik":1041934,"company_name":"EDAP TMS SA","ticker":"EDAP","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EDAP reports record 2025 HIFU revenue up 39% YoY; net loss widens, FY2026 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["HIFU revenue €33.1M in FY2025, +39% YoY; Focal One placements up 69% YoY.","Q4 HIFU revenue €11.7M (+34% YoY); Q4 U.S. procedures grew 28% YoY.","Q4 net loss €8.2M (€0.22/share) vs €1.9M (€0.05/share) prior year; operating loss €5.2M.","Q4 gross margin 42.6%, down from 44.8%, due to tariffs and inventory reserve; adjusted ~46.9%.","Reaffirms FY2026 revenue guidance $72-80M; core HIFU $50-54M (34-45% YoY growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":161547358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100599,"accession_number":"0001171843-26-001688","cik":1041934,"company_name":"EDAP TMS SA","ticker":"EDAP","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"EDAP TMS highlights 87 Focal One installs, 29% procedure CAGR in Oppenheimer presentation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["87 Focal One systems installed globally (42 academic, 45 community) as of Dec. 31, 2025.","Focal One procedures CAGR 29% and installations CAGR 52% from 2021 to 2025.","2026 hospital outpatient Medicare payment for HIFU remains $9,671 at APC Level 6.","HIFI trial (3,328 patients) showed 90% STFS vs 86% RP, superior continence and erectile function.","FARP randomized trial: 93.5% TFF at 3 years for focal ablation vs 91.5% RP, with better functional outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":161547358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100598,"accession_number":"0001171843-26-000769","cik":1041934,"company_name":"EDAP TMS SA","ticker":"EDAP","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"EDAP appoints David Horn to Board; Glen French resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glen French resigned from EDAP Board and all committees effective Feb 10, 2026; resignation not due to any dispute.","David Horn appointed to Board effective Feb 11, 2026, filling vacancy; will serve on Audit and Nominations Committees.","Horn is President and CFO of Seer, Inc., previously Managing Director at Morgan Stanley for 20 years in Healthcare Investment Banking.","Appointment subject to shareholder vote at next AGM; Horn compensated per director policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":161547358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100597,"accession_number":"0001171843-26-000204","cik":1041934,"company_name":"EDAP TMS SA","ticker":"EDAP","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"EDAP reports record Q4 HIFU revenue $12.9-13.3M; issues 2026 guidance $50-54M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 HIFU revenue $12.9-13.3M (record); FY2025 HIFU revenue $36.7-37.2M, up 36-38% YoY.","15 Focal One systems placed in Q4; FY2025 placements up 69% YoY.","US Focal One procedures grew 28% YoY in Q4; 87 systems installed globally as of Dec 31, 2025.","2026 HIFU revenue guidance $50-54M; non-core revenue guided $22-26M.","CEO highlights accelerating demand, clinical validation from HIFI and FARP trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":70527000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":161547358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}